Science Explorer Back to mapMap

Most cited papers from VenatoRx Pharmaceuticals (United States)

What are the most cited papers from VenatoRx Pharmaceuticals (United States)?

The most cited paper from VenatoRx Pharmaceuticals (United States) is "Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain" (JM Roberts-Lewis, MJ Savage, VR Marcy et al., 1994), with 322 citations. Next come "VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa" (220) and "Iron Acquisition Systems of Gram-negative Bacterial Pathogens Define TonB-Dependent Pathways to Novel Antibiotics" (153).

Showing 50 of 70 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain JM Roberts-Lewis, MJ Savage, VR Marcy et al. · Journal of Neuroscience Open access Jun 1994 322
2 VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa Jodie C. Hamrick et al. · Antimicrobial Agents and Chemotherapy Open access 18 Dec 2019 220
3 Iron Acquisition Systems of Gram-negative Bacterial Pathogens Define TonB-Dependent Pathways to Novel Antibiotics Phillip E. Klebba, Salete M. Newton, David A. Six et al. · Chemical Reviews ReviewOpen access 16 Mar 2021 153
4 Recent Advances in Amorphous Solid Dispersions: Preformulation, Formulation Strategies, Technological Advancements and Characterization Srushti M. Tambe, Divya D. Jain, Saikishore Meruva et al. · Pharmaceutics Open access 16 Oct 2022 127
5 International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II–Related Peptide, and Their Receptor: From Structure to Function Hubert Vaudry, Jérôme Leprince, David Chatenet et al. · Pharmacological Reviews Open access 23 Dec 2014 106
6 Substituted 1,2-Dihydrophthalazines: Potent, Selective, and Noncompetitive Inhibitors of the AMPA Receptor Jeffrey C. Pelletier, David P. Hesson, KENNETH ARTHUR JONES et al. · Journal of Medicinal Chemistry 1996 94
7 Desensitization of Kainate Receptors by Kainate, Glutamate and Diastereomers of 4-Methylglutamate KENNETH ARTHUR JONES, Timothy J. Wilding, James E. Huettner et al. · Neuropharmacology Jun 1997 83
8 In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program James A. Karlowsky, Meredith Hackel, Mark G G Wise et al. · Antimicrobial Agents and Chemotherapy Open access 21 Dec 2022 73
9 Cloning of the cDNA for the human NMDA receptor NR2C subunit and its expression in the central nervous system and periphery Yuzhong J. Lin, Sylvie Bovetto, Jeffrey M. Carver et al. · Molecular Brain Research Dec 1996 55
10 Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes Robert E. Lee Trout, Allison L. Zulli, Eugen F. Mesaros et al. · Journal of Medicinal Chemistry Open access 30 Jun 2021 48
11 Granzyme B Expression Is Enhanced in Human Monocytes by TLR8 Agonists and Contributes to Antibody-Dependent Cellular Cytotoxicity Saranya Elavazhagan, Kavin Fatehchand, Vikram Santhanam et al. · The Journal of Immunology Open access 10 Feb 2015 42
12 Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor James A. Dowell, Daniel Dickerson, Tim Henkel · Antimicrobial Agents and Chemotherapy Open access 9 Aug 2021 37
13 Differential effects of agents acting at various sites of the NMDA receptor complex in a place preference conditioning model Mariusz Papp, Elżbieta Moryl, Maria‐Luisa Maccecchini · European Journal of Pharmacology Dec 1996 36
14 Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of Enterobacterales Expressing Extended-Spectrum β-Lactamases and Serine Carbapenemases Cassandra L. Chatwin, Jodie C. Hamrick, Robert E. Lee Trout et al. · Antimicrobial Agents and Chemotherapy Open access 17 May 2021 35
15 1 ‐Aminocyclopropanecarboxylic Acid: Mouse to Man lnterspecies Pharmacokinetic Comparisons and Allometric Relationships Saul C. Cherkofsky · Journal of Pharmaceutical Sciences Oct 1995 35
16 Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment James A. Dowell, Thomas C Marbury, William Burton Smith et al. · Antimicrobial Agents and Chemotherapy Open access 3 Aug 2022 33
17 Fluorescent sensors of siderophores produced by bacterial pathogens Ashish Kumar, Taihao Yang, Somnath Chakravorty et al. · Journal of Biological Chemistry Open access 29 Jan 2022 30
18 Characterization of Poliovirus Variants Selected for Resistance to the Antiviral Compound V-073 Hongmei Liu, Jason Alexander Roberts, Deborah D. Moore et al. · Antimicrobial Agents and Chemotherapy Open access 13 Aug 2012 30
19 Cefepime–taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa : GEARS global surveillance programme 2018–22 James A. Karlowsky, Mark G G Wise, Meredith Hackel et al. · Journal of Antimicrobial Chemotherapy Open access 3 Sep 2024 26
20 The discovery and structure–activity relationships of pyrano[3,4-b]indole-based inhibitors of hepatitis C virus NS5B polymerase Randy W. Jackson, Matthew G. LaPorte, Torsten Herbertz et al. · Bioorganic & Medicinal Chemistry Letters 24 Apr 2011 23
21 Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection Greg Moeck, Leanne B. Gasink, Rodrigo Elisandro Mendes et al. · Antimicrobial Agents and Chemotherapy Open access 23 May 2024 22
22 Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance Collection James A. Karlowsky, Mark G G Wise, Meredith Hackel et al. · Antimicrobial Agents and Chemotherapy Open access 26 Oct 2022 20
23 1370. Cefepime/VNRX-5133 Broad-Spectrum Activity Is Maintained Against Emerging KPC- and PDC-Variants in Multidrug-Resistant K. pneumoniae and P. aeruginosa Denis M. Daigle, Jodie C. Hamrick, Cassandra L. Chatwin et al. · Open Forum Infectious Diseases Open access Nov 2018 18
24 The Next-Generation β-Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing Escherichia coli Elyse J. Roach, Tsuyoshi Uehara, Denis M. Daigle et al. · Microbiology Spectrum Open access 8 Sep 2021 16
25 Historical perspective of chemical warfare agents Nathan H. Johnson, Joseph C. Larsen, Edward C. Meek · Elsevier eBooks Book chapter 2020 15
26 ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime Michael R. Jacobs, Ayman M. Abdelhamed, Caryn E. Good et al. · Antimicrobial Agents and Chemotherapy Open access 12 Aug 2024 14
27 In vivo pharmacokinetics and pharmacodynamics of ceftibuten/ledaborbactam, a novel oral β-lactam/β-lactamase inhibitor combination Andrew J Fratoni, Lindsay M. Avery, David P Nicolau et al. · Journal of Antimicrobial Chemotherapy Open access 6 Oct 2022 13
28 731. CERTAIN-1: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP) Paul C. McGovern, Florian Wagenlehner, Leanne B. Gasink et al. · Open Forum Infectious Diseases Open access Dec 2022 12
29 Cefepime–taniborbactam and ceftibuten–ledaborbactam maintain activity against KPC variants that lead to ceftazidime–avibactam resistance Cullen L. Myers, Annie Stevenson, Brittany Miller et al. · Antimicrobial Agents and Chemotherapy Open access 10 Feb 2025 11
30 Motolimod effectively drives immune activation in advanced cancer patients Gregory N. Dietsch · OncoImmunology Open access 9 Feb 2016 11
31 Thrombosis of parietal, but not striate, cortex impairs acquisition of a 14-unit T-maze in the rat Edward L. Spangler, Brett Heller, John M. Hengemihle et al. · Physiology & Behavior Jul 1994 11
32 Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic Escherichia coli strains Tsuyoshi Uehara, Cassandra L. Chatwin, Brittany Miller et al. · Antimicrobial Agents and Chemotherapy Open access Apr 2025 7
33 Impact of porin deletions on cefepime-taniborbactam activity against Klebsiella pneumoniae Tsuyoshi Uehara, Cassandra L. Chatwin, Brittany Miller et al. · Antimicrobial Agents and Chemotherapy Open access 2 Apr 2025 6
34 ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten Michael R. Jacobs, Caryn E. Good, Ayman M. Abdelhamed et al. · Antimicrobial Agents and Chemotherapy Open access 30 Oct 2024 6
35 Cefepime-taniborbactam demonstrates potent in vitro activity vs Enterobacterales with bla OXA-48 María Fernanda Mojica, Elise T. Zeiser, Scott A. Becka et al. · Microbiology Spectrum Open access 24 Sep 2024 6
36 Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States María Fernanda Mojica, Elise T. Zeiser, Scott A. Becka et al. · Antimicrobial Agents and Chemotherapy Open access 28 Sep 2023 6
37 Cytotoxic effects of kainate ligands on HEK cell lines expressing recombinant kainate receptors Jeffrey M. Carver, Per‐Erik Mansson, Luz A. Cortes-Burgos et al. · Brain Research Open access May 1996 6
38 Diastereoselective synthesis of (2S,4R)-4-Methylglutamic acid (sym 2081): A high affinity and selective ligand at the kainate subtype of glutamate receptors Zi‐Qiang Gu, Xiao‐Fa Lin, David P. Hesson · Bioorganic & Medicinal Chemistry Letters Sep 1995 6
39 Establishing the reference broth microdilution MIC method for cefepime-taniborbactam Adam C. Belley, Susan M. Cusick, Dan C. Pevear et al. · Journal of Clinical Microbiology Open access 19 Aug 2025 4
40 Pharmacokinetics and safety of single and repeat doses of ceftibuten in healthy participants: a phase 1 dose escalation study Mary Beth Dorr, Carlos Fernando de Oliveira, Jeroen van de Wetering et al. · Antimicrobial Agents and Chemotherapy Open access 14 Aug 2025 4
41 Plasma and intrapulmonary pharmacokinetics of cefepime and taniborbactam in healthy adult participants Keith A. Rodvold, Mark H. Gotfried, Philip E. Sabato et al. · Antimicrobial Agents and Chemotherapy Open access 6 Jun 2025 4
42 Cefepime–Taniborbactam in Complicated Urinary Tract Infection Simone Lanini, Tommaso Cai, Carlo Tascini · New England Journal of Medicine 29 May 2024 4
43 Metabolic Incorporation of Azido-Sugars into LPS to Enable Live-Cell Fluorescence Imaging Inga Marie Nilsson, David A. Six · Methods in molecular biology Book chapter 2022 4
44 Assessment of human exposures of cefepime-taniborbactam against cefepime-resistant Enterobacterales and Pseudomonas aeruginosa in a 7-day hollow fiber infection model Lindsay M. Avery, Mitchell Edwards, Fan Yi et al. · Antimicrobial Agents and Chemotherapy Open access 31 Jul 2025 3
45 2523. Outcomes by Resistance Phenotype and Genotype among Baseline Pathogen in Patients with Complicated Urinary Tract Infection (cUTI) in the Phase 3 CERTAIN-1 Study Greg Moeck, Leanne B. Gasink, Mary Beth Dorr et al. · Open Forum Infectious Diseases Open access 27 Nov 2023 3
46 Gas chromatographic-mass spectrometric determination of urinary 1-aminocyclopropanecarboxylic acid in mice using a deuterated internal standard Sharon E. Howell, Scott R. Miller, J. David McCallister et al. · Journal of Chromatography B Biomedical Sciences and Applications 1995 3
47 Development of ACPC, A Partial Agonist of the Glycine Site on the NMDA Receptor Maria‐Luisa Maccecchini · Elsevier eBooks Book chapter 1997 3
48 In vivo activity of ceftibuten-ledaborbactam oral combination against serine-β-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model Christina Koenig, Fan Yi, David P Nicolau et al. · Journal of Antimicrobial Chemotherapy 7 Aug 2025 2
49 Safety and pharmacokinetics of single and multiple doses of ledaborbactam etzadroxil with or without ceftibuten in healthy volunteers Carlos Fernando de Oliveira, Mary Beth Dorr, Jeroen van de Wetering et al. · Antimicrobial Agents and Chemotherapy Open access 14 Aug 2025 2
50 Structure and mechanism of taniborbactam inhibition of the cefepime-hydrolyzing, partial R2-loop deletion Pseudomonas -derived cephalosporinase variant PDC-88 Andrew R Mack, Vijay Kumar, Christopher R. Bethel et al. · Antimicrobial Agents and Chemotherapy Open access 12 Jun 2025 2

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.